WO2004024711A1 - Derives de pyridine substitues utilises comme agent antitumoral - Google Patents

Derives de pyridine substitues utilises comme agent antitumoral Download PDF

Info

Publication number
WO2004024711A1
WO2004024711A1 PCT/EP2003/009572 EP0309572W WO2004024711A1 WO 2004024711 A1 WO2004024711 A1 WO 2004024711A1 EP 0309572 W EP0309572 W EP 0309572W WO 2004024711 A1 WO2004024711 A1 WO 2004024711A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolidin
diamine
pyridine
dichloro
pyridin
Prior art date
Application number
PCT/EP2003/009572
Other languages
English (en)
Inventor
Mauro Angiolini
Maria Menichincheri
Domenico Fusar Bassini
Markus Gude
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Priority to CA002498281A priority Critical patent/CA2498281A1/fr
Priority to EP03794969A priority patent/EP1546129A1/fr
Priority to JP2004535207A priority patent/JP2006503028A/ja
Priority to BR0314195-0A priority patent/BR0314195A/pt
Priority to AU2003260472A priority patent/AU2003260472A1/en
Priority to MXPA05001883A priority patent/MXPA05001883A/es
Publication of WO2004024711A1 publication Critical patent/WO2004024711A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Definitions

  • the present invention relates to novel substituted pyridine derivatives active as Telomerase inhibitors, to the use of them as therapeutic agents, in particular as antitumoral agents, to a process for their preparation and to • pharmaceutical compositions comprising them.
  • Cancer is one of the major causes of disease and the second leading cause of death in the western world. Most cancer patients still die due to metastatic disease. Despite the great increase in the knowledge and understanding of the regulatory mechanisms involved in the onset of malignancy, currently available treatments (including surgery, radiation and a variety of cytoreductive and hormone-based drugs, used alone or in combination) , are still highly non specific and toxic to the patient, causing severe side effects including nausea and vomiting, hair loss, diarrhea, fatigue and ulcerations. This evidence indicates the need for new and more effective anti-cancer therapies. Recently an understanding of the mechanisms by which normal cells reach the state of replicative senescence, i.e.
  • telomerase is a ribonucleoprotein enzyme responsible in most eukaryotes for the complete replication and maintenance of chromosome ends, or telomeres, which are composed of repeated DNA sequences (in particular human telomeres are formed by 5'-TTAGGG repeats). Telomerase binds to telomeric DNA using as a template a sequence contained within the RNA component of the enzyme necessary for the addition of the short sequence repeats to the chromosome 3' end (see Blackburn 1992, Annu . Rev. Biochem. , 61 , 113 -129) .
  • telomere activity cannot be detected and telomeres shorten with successive cell division: in fact actively dividing normal cells have the potential to lose 50- 200 base pairs after each round of cell division, finally resulting . in shortening of telomeres .
  • telomeres shortening will eventually lead to cellular senescence by various mechanisms.
  • telomere shortening in tumors and subsequent senescent phenotype (see Feng et al . Science, 1995, 269 , 1236-1241) . Moreover it has been recently shown ⁇ Hahn et al . Nature Med .
  • telomere shortening can cause telomere shortening and arrest of cell growth and apoptosis.
  • peptide-nucleic .acids, and 2 ' -O-MeRNA oligomers complementary 'to-, the template region of the RNA component of the- enzyme .. have been reported to cause inhibition of telomerase ' activity, telomere shortening and cell death in certain tumor cell lines (see Herbert et al .
  • telomere activity can be used to treat cancer, as cancer cells express telomerase activity, while normal human somatic cells usually do not express telomerase activity at biologically relevant levels (i.e., at levels sufficient to maintain telomere length over many cell divisions) . Also telomere length in tumors is reduced compared with non-transformed cells giving the possibility of a therapeutic window (see Nakamura et al . Cancer Letters 158, 2000, 179-184) . Therefore a need exists to find molecules that inhibit the activity of telomerase and interfere with the growth of many types of cancer.
  • the present invention fulfills such a need by providing a high general method of treating many - if not most malignancies, as demonstrated by the highly number of human tumor cell lines and tumors having telomerase activity.
  • the compounds of the present invention can be effective in providing treatments that discriminate between malignant and normal cells to a high degree, avoiding many of the deleterious side-effects present with most current chemotherapeutic regimes which rely on agents that kill
  • Embodiments of the present invention are substituted pyridine derivatives having the following formula (I)
  • R4 represents hydrogen or C1-C4 alkyl and R5 represents an unsubstituted or substituted C1-C18 n-alkyl or C3-C6 cycloalkyl ; or b) R4 and R5 taken together with N to which they are linked represent an unsubstituted or substituted saturated 5 to 7 membered heterocyclic ring;
  • halogen atom we intend a chlorine, bromine, fluorine or iodine atom.
  • C1-C18 n-alkyl we intend a straight alkyl chain having a carbon chain length of from 1 to 18 carbon atoms, unsubstituted or substituted by a group selected from C1-C4 alkoxycarbonyl, C1-C4 alkoxy, adamantyl, 2 ' -tetrahydrofuryl, methylene dimethoxy. or phenyl unsubstituted or substituted by C1-C4 alkoxy or C3-C6 cycloalkyl.
  • C1-C18 n-alkyl is an unsubstituted C18 straight alkyl chain or a C1-C4 straight alkyl chain unsubstituted or substituted by a group selected from C1-C4 alkoxycarbonyl, C1-C4 alkoxy, adamantyl, 2 ' -tetrahydrofuryl, methylene dimethoxy or phenyl unsubstituted or substituted by from 1 to 3 C1-C4 alkoxy or C3-C6 cycloalkyl.
  • C1-C4 alkyl we intend a group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl group.
  • C3-C6 cycloalkyl we intend a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
  • C1-C4 acyl we intend, for instance, formyl, acetyl , and propanoyl .
  • C1-C4 alkoxy is typically methoxy, ethoxy, propoxy or butoxy.
  • R4 and R5 form a 5 to 7 membered saturated heterocycle ring with the nitrogen atom to which they are linked, one carbon atom may be further replaced by heteroatoms such as nitrogen, oxygen and sulphur.
  • 5 to 7 membered optionally substituted saturated heterocyclic rings according to the present invention are pyrrolidine, pyrroline, pyrazolidine, pyrazoline, piperidine, piperazine, N-C1-C4 alkyl piperidine, N-C1-C4 alkyl-piperazine, N-phenyl piperazine, N-benzyl piperazine, N-pyrimidinyl piperazine, N- C1-C4 alkoxycarbonyl piperazine, morpholine, and the like.
  • salts of the compounds of formula (I) are, e.g., the acid addition salts with inorganic or organic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid.
  • a preferred class of compounds of the present invention is represented by compounds of formula (I) above wherein: n is 1;
  • R represents hydrogen; Rl and R2 represent either both hydrogen or both Cl;
  • R3 represents NR4R5 wherein a') R4 represents hydrogen or C1-C4 alkyl, and R5 represents C1-C18 n-alkyl unsubstituted or substituted by adamantyl, 2 ' -tetrahydrofuryl, methylene dimethoxy CH(OMe)2, phenyl unsubstituted or substituted by C1-C4 alkoxy or C3-C6 cycloalkyl; or b ' ) R4 and R5 taken together with N to which they are linked represent an unsubstituted or substituted 5-7 membered saturated heterocyclic ring represented by the following formulae:
  • R6 represents hydrogen, methyl, phenyl, benzyl, ethoxycarbonyl (COOEt)or 2-pyriminidinyl; and the pharmaceutically acceptable salts thereof.
  • Examples of preferred compounds of the present invention, whenever appropriate in the form pharmaceutically acceptable salts, e.g. with hydrochloric or hydrobromic acid are listed, but not limited to, the following ones: 1)2- (4-Phenyl-piperazin-l-yl) -6-pyrrolidin-l-yl-pyridin-4- ylamine;
  • a further embodiment of the present invention is to provide a process for the preparation of compounds of formula (I) as defined above according to the method described in the following Scheme 1.
  • Hal is a halogen atom, i.e. Cl, Br, I or F; and n, R, R4 and R5 have the same meanings as reported in formula ( I ) above .
  • Compounds of formula (II) may be easily prepared starting from commercially available reagents following procedures well known in the art or they are commercially available from, for example, Aldrich Catalogue.
  • Novel intermediates of formula (III) may be prepared by reacting a compound of formula (II) with a proper nucleophile, i.e. an amine of formula (IV), wherein R4 and R5 are as defined above.
  • a proper nucleophile i.e. an amine of formula (IV)
  • R4 and R5 are as defined above.
  • proper reaction conditions for this transformation involve temperatures ranging from room temperature to reflux conditions in an organic solvent such as, for example, methanol, ethanol, isopropanol, n-buthanol, t-buthanol, tetrahydrofuran, dioxane, ethyl acetate, toluene or N-methyl-pyrrolidone for a time ranging from 30' to 24h, using 1 or more equivalents of amine of formula (IV) in high yield improving methods reported in the literature (see for example J " . Org. Chem . 1990, 55, 4992) .
  • Novel intermediates of formula (III) are then reacted with an amine of formula (V), i.e. pyrrolidine or piperidine, to get a compound of general formula (lb), i.e. a compound of formula
  • R is hydrogen and Rl and R2 are both halogen, in an organic solvent like methanol, ethanol, isopropanol, n- buthanol , t-buthanol, tetrahydrofuran, dioxane, ethyl acetate, toluene or N-methyl-pyrrolidone, at a temperature ranging from room temperature to reflux conditions for a time which may vary from 30' to 24h, using 1 or more equivalents of a compound of formula (V) , in high yield improving methods reported in the literature (see for example J " . Org. Chem. 1990, 55, 4992) .
  • a compound of formula (lb) may be converted in to a compound of formula (Ic) , i.e. a compound of formula (I) wherein R, Rl and R2 are hydrogen, under hydrogenolytic conditions, for example in ethanol or methanol as the solvent, by using ammonium formate as the source of hydrogen and Pd/C as catalyst at room temperature .
  • Other hydrogenolitic conditions can be applied (see, for example, classical hydrogenolysis in J " . March “Advanced Organic Chemistry", III Edition, Wiley - Interscience Publ . ) but the previous method is particularly suitable for parallel synthesis.
  • the stepwise solution phase method outlined in Scheme 1 has been conveniently adapted for the parallel synthesis of multiple analogs of general formula (Ic) in one shot.
  • Compounds of formula (lb) and (Ic) may be converted by acylation into compounds of formula (Ie) , i.e. compounds of formula (I) wherein R is C1-C4 acyl and Rl and R2 are both halogen, and (Ic) , i.e. compounds of formula (I) wherein R is C1-C4 acyl and Rl and R2 are both hydrogen, respectively, in dry pyridine under argon pressure, at temperatures ranging from 0° to 5° C, in presence of a catalytic amount of dimethylamino pyridine (DMAP) and corresponding chlorides as reagents .
  • DMAP dimethylamino pyridine
  • a compound of formula (I) may be converted into a pharmaceutically acceptable salt thereof using the suitable pharmaceutically acceptable acid, following the procedures well know in the art .
  • telomerase activity of compounds of the invention have been evaluated using a FlashPlate ® -based assay (PerkinElmer, Boston, Mass.) .
  • the method proved to be sensitive, accurate and able to reproducibly identify compounds that inhibit telomerase activity in a dose-dependent manner.
  • the assay mixture is constituted of:
  • telomerase enzyme diluted in a buffer, the composition of which has been selected to maintain the enzyme activity stable along the duration of the assay.
  • test compounds/positive control - increasing concentrations of test compounds/positive control .
  • telomeric repeats added are evaluated by hybridization in solution with a 3' -labeled short oligonucleotide probe.
  • FlashPlate ® where the binding between biotin and streptavidin occurs .
  • telomerase activity is proportional to the radioactivity measured and the inhibitory activity of the compounds is evaluated as IC 50 using the Sigma Plot fit program.
  • a human or animal body can thus be treated by a method, which comprises the administration of a pharmaceutically effective amount of a compound of formula (I) or a salt thereof.
  • the condition of the human or animal can thereby be improved.
  • Compounds of the invention can be used to treat, prevent, and/or ameliorate tumors and cancer.
  • the present invention provides a pharmaceutical composition, which comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable excipient or carrier.
  • the present invention also provides methods for the preparation of a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which comprises admixing a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient or carrier.
  • Pharmaceutical compositions of the invention containing pharmaceutically acceptable excipients or carriers and a compound of the invention can be prepared by any of the well known techniques of pharmacy that comprise admixing the excipients or carriers with a drug or therapeutic agent.
  • compositions of the present invention can be formulated and used as, e.g., tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for injectable administration, and the other compositions known in the art.
  • a pharmaceutical composition refers to a composition in a form suitable for administration, e.g., systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapul onary and intramuscular.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington 's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein.
  • preservatives, stabilizers, dyes and flavoring agents can be provided.
  • antioxidants and suspending agents can be used.
  • the pharmaceutical compositions containing compounds of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets can be uncoated or they can be coated by known techniques . In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monosterate or glyceryl distearate can be employed.
  • Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
  • compositions of the invention can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil or mixtures of these.
  • Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions can also contain sweetening and flavoring agents.
  • Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • Suitable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono-or diglycerides .
  • fatty acids such as oleic acid find use in the preparation of injectables .
  • the specific dose of a compound administered according to this invention to obtain a therapeutic effect will, of course, be determined by the particular circumstances surrounding the administration, including, for example, the age, weight, condition of the patient, gender, diet, time of administration, rate of excretion, drug combination, severity of disease, and administration route; specific dosage regimens can be fit to any particular subject on the basis of the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compounds.
  • the dosage range adopted will depend on the route of administration and on the age, weight and condition of the patient being treated.
  • daily doses of the compounds of the invention typically administered by parenteral route, for example, intravenously by bolus or infusion is from 1 to 1000 mg/m 2 body surface area, for instance from 10 to 500 mg/m 2 .
  • the dosages can be administered at once or can be divided into a number of smaller doses to be administered at varying intervals.
  • a pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state.
  • the pharmaceutically effective dose depends on, for example, the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize.
  • Compounds and pharmaceutical compositions according to the invention are useful for the prevention, amelioration, and/or treatment of benign and malignant tumors or neoplasias including cancer, such as, for example, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, gastrointestinal cancer, colorectal cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, pancreatic cancer, lung cancers, breast cancer and skin cancer, prostate cancer, and renal cell carcinoma.
  • a method for treating a patient having a cancer or tumor which comprises administering a therapeutically effective amount
  • the invention further comprises methods of treatment, prevention, or amelioration of benign and malignant tumors or neoplasias comprising administering a pharmaceutically effective amount of a compound of the invention to a subject in need thereof such that the benign or malignant tumor or neoplasia is treated, prevented or ameliorated.
  • N*2*-cyclohexyl-6-pyrrolidin-l-yl-pyridine-2, 4-diamine (2) : X H-NMR (400Mhz, CDC1 3 ) , ppm: 1.06-2.12 (m, 14H) , 3.37 (m, 5H) , 3.67 (sb, 2H) , 4.16 (sb, IH) , 5.08 (s, IH) , 5.10 (s, IH) .
  • N*2*-methyl-6-pyrrolidin-l-yl-pyridine-2, 4-diamine (9) X H- NMR (400Mhz, CDC1 3 ) , ppm: 1.88 (m, 4H) , 2.78 (s, 3H) , 3.40 (m, 4H) , 3.76 (sb, 2H)., 4.25 (sb, IH) , 5.05 (s, IH) , 5.10 (s, IH) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de pyridine substitués utilisés comme inhibiteurs de la télomérase. Elle concerne l'utilisation de ces dérivés comme agnts thérapeutiques, en particulier comme agents antitumoraux; un procédé de préparation et des compositions pharmaceutiques contenant ces dérivés.
PCT/EP2003/009572 2002-09-10 2003-08-26 Derives de pyridine substitues utilises comme agent antitumoral WO2004024711A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002498281A CA2498281A1 (fr) 2002-09-10 2003-08-26 Derives de pyridine substitues utilises comme agent antitumoral
EP03794969A EP1546129A1 (fr) 2002-09-10 2003-08-26 Derives de pyridine substitues utilises comme agent antitumoral
JP2004535207A JP2006503028A (ja) 2002-09-10 2003-08-26 抗腫瘍薬としての置換ピリジン誘導体
BR0314195-0A BR0314195A (pt) 2002-09-10 2003-08-26 Derivados de piridina substituìda como agentes antitumorais
AU2003260472A AU2003260472A1 (en) 2002-09-10 2003-08-26 Substituted pyridine derivatives as antitumor agent
MXPA05001883A MXPA05001883A (es) 2002-09-10 2003-08-26 Derivados de piridina sustituidos como agentes antitumorales.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40947102P 2002-09-10 2002-09-10
US60/409,471 2002-09-10

Publications (1)

Publication Number Publication Date
WO2004024711A1 true WO2004024711A1 (fr) 2004-03-25

Family

ID=31993972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009572 WO2004024711A1 (fr) 2002-09-10 2003-08-26 Derives de pyridine substitues utilises comme agent antitumoral

Country Status (7)

Country Link
EP (1) EP1546129A1 (fr)
JP (1) JP2006503028A (fr)
AU (1) AU2003260472A1 (fr)
BR (1) BR0314195A (fr)
CA (1) CA2498281A1 (fr)
MX (1) MXPA05001883A (fr)
WO (1) WO2004024711A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123936A1 (fr) * 2006-04-19 2007-11-01 Laboratoires Serono Sa Nouveaux dérivés d'arylaminopyridine substitués par un hétéroaryle, en tant qu'inhibiteurs de mek
WO2008122378A1 (fr) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
WO2009104990A1 (fr) * 2008-02-21 2009-08-27 Общество С Ограниченной Ответственностью "Валексфарм" Dérivés de 2,4-diaminopyridine, composition pharmaceutique, produit médicinal à base desdits dérivés destinés au traitement ou à la prévention de maladies et troubles provoqués par l’hyperactivation de récepteurs nmda et/ou en tant que stimulateurs de fonctions congnitives et procédé d’utilisation correspondant
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN107935991A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一种甲基金刚烷和胺基吡啶结构衍生物、其制备方法及其用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108129457A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷ssao抑制剂、制备方法及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2139042A1 (de) * 1970-08-04 1972-02-10 Ici Ltd Dipyridylaminverbindungen, Verfahren zu deren Herstellung und deren Verwendung
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2139042A1 (de) * 1970-08-04 1972-02-10 Ici Ltd Dipyridylaminverbindungen, Verfahren zu deren Herstellung und deren Verwendung
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MENICHINCHERI, MARIA ET AL: "Parallel synthesis of 4-amino-2,6-dialkylaminopyridines", TETRAHEDRON LETTERS (2002), VOLUME DATE 2003, 44(3), 519-522, XP002263229 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123936A1 (fr) * 2006-04-19 2007-11-01 Laboratoires Serono Sa Nouveaux dérivés d'arylaminopyridine substitués par un hétéroaryle, en tant qu'inhibiteurs de mek
US8076486B2 (en) 2006-04-19 2011-12-13 Merck Serono S.A. Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
WO2008122378A1 (fr) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
WO2009104990A1 (fr) * 2008-02-21 2009-08-27 Общество С Ограниченной Ответственностью "Валексфарм" Dérivés de 2,4-diaminopyridine, composition pharmaceutique, produit médicinal à base desdits dérivés destinés au traitement ou à la prévention de maladies et troubles provoqués par l’hyperactivation de récepteurs nmda et/ou en tant que stimulateurs de fonctions congnitives et procédé d’utilisation correspondant
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN107935991A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一种甲基金刚烷和胺基吡啶结构衍生物、其制备方法及其用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108129457A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷ssao抑制剂、制备方法及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途

Also Published As

Publication number Publication date
CA2498281A1 (fr) 2004-03-25
MXPA05001883A (es) 2005-06-03
EP1546129A1 (fr) 2005-06-29
JP2006503028A (ja) 2006-01-26
BR0314195A (pt) 2005-07-26
AU2003260472A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
EP1546129A1 (fr) Derives de pyridine substitues utilises comme agent antitumoral
JP6842458B2 (ja) 治療化合物としてのｎ−（ピリジン−２−イル）−４−（チアゾール−５−イル）ピリミジン−２−アミン誘導体
JP5075624B2 (ja) シアノピリジン誘導体及びその医薬としての用途
JP6902065B2 (ja) 癌の処置のための化合物
EP2001890B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs utilisation pour le traitement des maladies proliferatives
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
EP3613737A1 (fr) Nouvel inhibiteur de kinase cdk9 dépendant de la cycline
CN109890784B (zh) 取代的羟基均二苯乙烯及其治疗应用
JP6887430B2 (ja) 重水素化されたＢｒｉｇａｔｉｎｉｂ誘導体、かかる誘導体を含む薬学的組成物、並びにそれらの使用
CN111386266B (zh) 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物
US9790158B2 (en) Substituted tropolone derivatives and methods of use
CN116410207A (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
WO2016015676A1 (fr) Inhibiteurs de protéine kinase 2-aminopyridine substitués par pyridine
EP2940022A1 (fr) Furopyridines comme inhibiteurs de protèines kinases
WO2016023028A2 (fr) Inhibiteurs de la kinase du récepteur couplé aux protéines g 2 et procédés d'utilisation de ceux-ci
US9745257B2 (en) Phenyl-guanidine derivatives
CN115477639B (zh) 一种以fgfr1为靶点的多取代嘧啶类化合物及其制备方法和用途
WO2022236256A1 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase
CN110950807B (zh) 联芳基类化合物、其制备方法、药物组合物及其应用
CN106146468B (zh) 吡啶酮类蛋白激酶抑制剂
KR20140044790A (ko) 피페라진디온 화합물
CA3184218A1 (fr) Composes d'oxyde d'arylphosphine et leur utilisation
CN114805359A (zh) 炔代杂环化合物fgfr抑制剂的制备方法和用途
KR100392468B1 (ko) 사이클린 의존 키나아제의 저해제로서 유용한3-히드록시크로멘-4-온 유도체

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001883

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003794969

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2498281

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004535207

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003794969

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003794969

Country of ref document: EP